Brian G.M. Durie

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial”.

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30354-9

N/A

3.8DataRank · unranked

126 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Hita +12 more

Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8507

N/A

0DataRank · unranked

26 citations

Sikander Ailawadhi, Rachael Sexton, Antje Hoering, Brea Lipe, Sandi Hita +9 more

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Blood Cancer Journal(2020)10.1038/s41408-020-0311-8

N/A

0DataRank · unranked

252 citations

Antje Hoering, Rachael Sexton, Muneer H. Abidi, Joshua Epstein, S. Vincent Rajkumar +8 more

Randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (SWOG-1211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8054

N/A

0DataRank · unranked

4 citations

Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Jason Valent +11 more

Prior cancer and risk of monoclonal gammopathy of undetermined significance: a population-based study in Iceland and Sweden

Haematologica(2024)10.3324/haematol.2023.284365

N/A

0DataRank · unranked

1 citations

Sigrún Þorsteinsdóttir, Elisavet Syriopoulou, Ingigerður Sverrisdóttir, Ingemar Turesson, Elías Eyþórsson +20 more

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

Blood Cancer Journal(2025)10.1038/s41408-025-01259-z

N/A

0DataRank · unranked

34 citations

Sireesha Asoori, Chiung‐Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis +19 more

Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study

Blood Cancer Journal(2021)10.1038/s41408-021-00580-7

N/A

0DataRank · unranked

11 citations

Elías Eyþórsson, Sigrún Þorsteinsdóttir, Brynjar Viðarsson, Páll T. Önundarson, Bjarni A. Agnarsson +24 more